Online Catalog
A collection of nonclinical studies & assays; customization is possible.

Flu Model: H1N1 influenza lung infection model – viral COPD exacerbation

Influenza virus infection in humans results in a respiratory disease that ranges in severity from sub-clinical infection to primary viral pneumonia. 40-60 % of acute exacerbations in COPD are associated with respiratory virus infection; 85 % of asthma attacks in children and 44 % in adults are precipitated by upper respiratory tract infection.

For the assessment of anti-virals there is an on-site microbiology Department who will prepare, assess the viral dose and can assess viral load in the lung tissue.  

This model is also useful for assessing anti-inflammatories targeted at viral respiratory induced inflammation. We also have experience of using a steroid as a positive control.

The severity and length of the model can easily be manipulated by adjustment of the initial viral titre.

Charts from the H1N1 Study
Study Design

Balb/c or C57BL/6J mouse, ferret

Model H1N1 influenza lung infection model
Relevant Use Screening and assessment of new anti-viral and anti-inflammatory drugs for viral respiratory disease
Readouts Available Daily Bodyweights and Clinical Signs, Lung Function (penH, Resistance, Compliance, FEV) Viral load, BAL differential cell counts, BAL cytokines and Pathology

Study data generated by Labcorp Huntingdon Pharmacology.